Source - RNS
RNS Number : 8628K
GlaxoSmithKline PLC
26 September 2016
 

GlaxoSmithKline plc (the 'Company')

Transaction notification

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R G Connor

b)

Position/status

President, Global Manufacturing & Supply

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

  

 

b)

Nature of the transaction

Following the vesting on 23 September 2016 of 50% of an award made on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award Plan, Mr R Connor will receive a cash payment of £237,076.13 less applicable tax withholding in respect of 14,376.963 notional Ordinary Shares.

 

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£16.49

14,376.963 notional Ordinary Shares.

 

 

 

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

e)

Date of the transaction

2016-09-23

f)

Place of the transaction

 

n/a

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr S A Hussain

b)

Position/status

President, Global Pharmaceuticals

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

 

b)

Nature of the transaction

Following the vesting on 23 September 2016 of 50% of an award made on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award Plan, Mr Hussain will receive a cash payment of £296,345.16 less applicable tax withholding in respect of 17,971.204 notional Ordinary Shares.

 

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£16.49

17,971.204 notional Ordinary Shares

 

 

 

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

e)

Date of the transaction

2016-09-23

f)

Place of the transaction

 

n/a

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D S Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

 

b)

Nature of the transaction

Following the vesting on 23 September 2016 of 50% of an award made on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award Plan, Mr Redfern will receive a cash payment of £237,076.13 less applicable tax withholding in respect of 14,376.963 notional Ordinary Shares.

 

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£16.49

14,376.963 notional Ordinary Shares

 

 

 

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

e)

Date of the transaction

2016-09-23

f)

Place of the transaction

 

n/a

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms C Thomas

b)

Position/status

SVP, Human Resources

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

   

 

b)

Nature of the transaction

Following the vesting on 23 September 2016 of 50% of an award made on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award Plan, Ms Thomas will receive a cash payment of £237,076.13 less applicable tax withholding in respect of 14,376.963 notional Ordinary Shares.

 

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£16.49

14,376.963 notional Ordinary Shares

 

 

 

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

e)

Date of the transaction

2016-09-23

f)

Place of the transaction

 

n/a

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr P J T Vallance

b)

Position/status

President, Pharmaceuticals Research & Development

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

 

b)

Nature of the transaction

Following the vesting on 23 September 2016 of 50% of an award made on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award Plan, Mr Vallance will receive a cash payment of £296,345.16 less applicable tax withholding in respect of 17,971.204 notional Ordinary Shares.

 

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£16.49

17,971.204 notional Ordinary Shares

 

 

 

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

e)

Date of the transaction

2016-09-23

f)

Place of the transaction

 

n/a

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHEQLFLQKFEBBK

Related Charts

GlaxoSmithKline (GSK)

-1.50p (-0.10%)
delayed 18:15PM